Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 12/8/2020
SIETES contiene 93083 citas

 
 
 1 a 20 de 117 siguiente >>
Presentar resultados
Seleccionar todas
1. Cita con resumen
Wood AJJ, Drazen JM, Greene MF. The politics of emergency contraception. N Engl J Med 2012;366:101-2. [Ref.ID 92165]
2. Cita con resumen
Anónimo. Spain sees rise in demand for emergency contraception. BMJ 2009;339:1104. [Ref.ID 87086]
3. Cita con resumen
Fjerstad M, Trussell J, Sivin I, Lichtenberg ES, Cullins V. Rates of serious infection after changes in regimens for medical abortion. N Engl J Med 2009;361:145-51. [Ref.ID 86168]
4. Cita con resumen
Anónimo. Which approach for first trimester miscarriage?. Drug Ther Bull 2009;47:77-80. [Ref.ID 86135]
5.Tiene citas relacionadas Cita con resumen
Angell M. Industry-sponsored clinical research. A broken system. JAMA 2008;300:1069-71. [Ref.ID 83907]
6. Cita con resumen
Bos-Thompson M-A, Hillaire-Buys D, Roux C, Faillie JL, Amram D. Möbius syndrome in a neonate after mifepristone and misoprostol elective abortion failure. Ann Pharmacother 2008;42:888-92. [Ref.ID 83196]
7.
Taddia A, Zeni B, Campomori A, Campi R. Mifepristone e misoprostolo: efficacia e sicurezza nell'aborto medico. Ricerca & Pratica 2008;24:3-16. [Ref.ID 82521]
8.Enlace a cita original Cita con resumen
9.Tiene citas relacionadas Cita con resumen
Kongnyuy EJ, Wiysonge CS. Misoprostol and pregnancy termination. Lancet 2007;370:1824-5. [Ref.ID 81657]
10. Cita con resumen
Anónimo. EMEA upholds efficacy of abortifacient combination. Scrip 2007;3247:20. [Ref.ID 79746]
11. Cita con resumen
Campbell OMR, Graham WJ, on behalf of The Lancet Maternal Survival Series steering group. Strategies for reducing maternal mortality: getting on with what works. Lancet 2006;368:1284-99. [Ref.ID 78143]
12. Cita con resumen
Anónimo. Mifepristone. Two additional sepsis deaths. USA. WHO Pharmaceuticals Newsletter 2006;3:3-4. [Ref.ID 77503]
13.
Ornstein RM, Fisher MM. Hormonal contraception in adolescents: special considerations . Pediatr Drugs 2006;8:25-45. [Ref.ID 76687]
14.
Gary MM, Harrison DJ. Analysis of severe adverse events related to the use of mifepristone as an abortifacient. Ann Pharmacother 2006;40:191-7. [Ref.ID 76302]
15. Cita con resumen
Anónimo. Australia set for a fiery debate on abortion drug. Scrip 2005;3113:18. [Ref.ID 75631]
16.
Greene MF. Fatal infections associated with mifepristone-induced abortion. N Engl J Med 2005;353:2317-8. [Ref.ID 75581]
17. Cita con resumen
Anónimo. WHO Model List of Essential Medicines. WHO Drug Information 2005;19:222-35. [Ref.ID 75414]
18.
Anónimo. Highlights of the 14th Model List of Essential Medicines. WHO Drug Information 2005;19:220. [Ref.ID 75413]
19.
Anónimo. Mifepristone: revised safety information. Switzerland. WHO Drug Information 2005;19:211. [Ref.ID 75406]
20.
Anónimo. Mifepristone, sepsis and blood infection. United States of America. WHO Drug Information 2005;19:211. [Ref.ID 75405]
Seleccionar todas
 
 1 a 20 de 117 siguiente >>